NRT Raises RMB 1 Billion Series E Financing, with CEC Capital Serving as Exclusive Financial Advisor

Chengdu New Radiomedicine Technology Co., Ltd. ("NRT") recently announced the successful closing of its RMB 1 billion Series E financing. This round was co-led by Shanghai STVC Group, Shanghai Guoxin and Neovision Capital, with participation from multiple institutional investors including Highlight Capital.

CEC Capital acted as the Exclusive Financial Advisor to NRT in connection with this financing.

The successful closing of this financing fully demonstrates the market’s recognition of NRT’s development prospects. The proceeds raised will be primarily allocated to the clinical development of core radiopharmaceutical pipelines, the R&D and production of medical isotopes, and market expansion, so as to consolidate the company’s leading position in China’s medical isotope and radiopharmaceutical sectors.

Founded in 2016, NRT has been dedicated to the innovative R&D, production and sales of medical isotopes and radiopharmaceuticals. The company boasts a robust pipeline of innovative radiopharmaceuticals under development, including Yttrium [90Y] Carbon Microsphere Injection and radionuclide-conjugated drugs, which are primarily indicated for the diagnosis and treatment of various cancers such as liver cancer, pancreatic cancer and prostate cancer.

To date, NRT has established a world-class R&D and production base for medical isotopes and pharmaceutical products. Through strategic cooperation with international pharmaceutical and medical device companies, the company has accelerated the localized production and commercialization of cutting-edge radiopharmaceuticals, striving to deliver high-quality medical solutions to patients in China and worldwide.